Kevin Hart
Scientific Director & Associate Research Fellow Pfizer
Seminars
Wednesday 16th September 2026
Targeting Thyroid Hormone Receptor-Β Pathways To Reduce Liver Fibrosis, Improve Metabolic Function & Enable Durable Clinical Benefit In Mash
9:30 am
- Evaluating the role of liver-directed metabolic therapies in addressing interconnected drivers of steatosis, inflammation and fibrosis to enhance therapeutic impact, enabling more comprehensive disease management and improving long-term patient outcomes
- Modulating liver-specific metabolic pathways to improve lipid handling and reduce inflammatory signaling, strengthening anti-fibrotic efficacy and improving disease resolution potential
- Developing differentiated metabolic therapies with scalable combination potential to address persistent unmet need in MASH, improving treatment durability and future therapeutic positioning
